Poziotinib Shows Promise In EGFR Exon 20 Mutant NSCLC
Executive Summary
Hanmi and Spectrum's novel oral pan-HER inhibitor poziotinib shows promising interim results in Phase II study in NSCLC patients with EGFR exon 20 insertion mutations, an unmet need.
You may also be interested in...
Spectrum To Test Poziotinib's Potential As First Line Treatment Of Exon 20 Mutant NSCLC
Spectrum is expanding a clinical trial with its novel, oral pan-HER inhibitor poziotinib into the first-line treatment of NSCLC with EGFR or HER2 exon 20 insertion mutations, which could provide a much-needed new option for these patients. The move also marks further positive development progress for the drug, which the US firm licensed in from Hanmi.
Tech Transfer Roundup: Amgen Teams With MD Anderson To Accelerate Early-Stage Cancer Candidates
In a busy month, MD Anderson also partners with Ipsen on an unspecified cancer drug and licenses poziotinib IP to Spectrum. Using IP from UCLA, Bloom launches with focus on neuroprotective epilepsy therapies.
Hanmi Halts Olmutinib Development After Alliances Crumble
Hanmi is set to focus on other assets in its innovative drug pipeline after it ends development of novel lung cancer drug olmutinib amid ZAI Lab’s recent cancellation of a licensing agreement with the South Korean pharma.